M Pharmaceutical Inc. announced that it has entered into a manufacturing supply agreement with Rishena Co., Ltd., to manufacture the company's Trimtec gastric functional neurostimulation device. Under the terms of the agreement, Rishena will be the exclusive supplier of laparoscopically-implantable Trimtec devices to M Pharmaceutical for the North and South American markets. The devices will be fully programmable and rechargeable through an abdominal belt.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | +9,900.00% | -.--% | +9,900.00% |
2018 | James Thompson to Assume the Position of President and Chief Executive Officer of Callitas Health Inc | CI |
2018 | Callitas Health Inc. Announces Management Changes | CI |
1st Jan change | Capi. | |
---|---|---|
+9,900.00% | 4.53K | |
+23.37% | 46.71B | |
+48.83% | 41.8B | |
-0.94% | 41.52B | |
-5.86% | 29.55B | |
+11.29% | 25.78B | |
-20.92% | 19.26B | |
+3.20% | 12.14B | |
-2.67% | 12.08B | |
+30.23% | 11.98B |
- Stock Market
- Equities
- MPHMF Stock
- News Callitas Health Inc.
- Rishena Enters Into Manufacturing Supply Agreement for Production of Trimtec Gastric Stimulation Device